Human papillomavirus vaccine TA-CIN - Cancer Research Technology

Drug Profile

Human papillomavirus vaccine TA-CIN - Cancer Research Technology

Alternative Names: TA-CIN; Therapeutic HPV vaccine - Cancer Research Technology

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xenova Group
  • Class Cancer vaccines; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Human papillomavirus infections

Highest Development Phases

  • Phase II Vulvar intraepithelial neoplasia
  • No development reported Cervical dysplasia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cervical-dysplasia in Netherlands (Parenteral, Injection)
  • 09 Oct 2017 Sidney Kimmel Comprehensive Cancer Center plans a phase I trial for Cervical cancer (Adjuvant therapy) in USA (NCT02405221)
  • 29 Jul 2015 TA-CIN is still in active development with non-industrial organisations
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top